More Pharma Firms In China Diversify With Direct Sales Of Consumer Products
This article was originally published in The Tan Sheet
Under the influence of the changing pharmaceutical policy environment, China's pharmaceutical companies are experiencing a development bottleneck. Upgrading to new business model and finding new ways of doing so have become a reality of choice for many companies. More and more pharmas are tapping into the opportunities of direct sale, including A-share market-listed and state-owned companies, bringing total to 10 pharmas.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.